SAB Biotherapeutics, Inc. (SABS) stock
SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$3.20+0.25 (+8.47%)
Close on Nov 18, 2026Market cap $291.16MP/E –Yield –
SAB Biotherapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
SAB Biotherapeutics's pe ratio was 13.4× on Apr 30, 2026, against 23.6× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Apr 30, 2026 | 13.4× | +3.9 |
| 2025 | Dec 31, 2025 | 9.5× | −4.4 |
| 2022 | Jan 31, 2022 | 13.9× | −4.8 |
| 2021 | Dec 31, 2021 | 18.6× | – |
See a number that looks wrong?